Intravenous Immunoglobulin Reduces Infections for Patients with Chronic Lymphocytic Leukemia: A Single-Center...

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Hypogammaglobulinemia is a frequent complication in chronic lymphocytic leukemia (CLL).
• Previous research indicated intravenous immunoglobulin (IVIG) reduces infections but offers no survival advantage in CLL patients.
• The evolving treatment landscape for CLL necessitates re-evaluating IVIG's role.

Purpose of the Study:

• To assess the impact of IVIG on infectious outcomes in CLL patients.
• To evaluate IVIG's efficacy across different CLL treatment eras, including targeted therapies.
• To determine if IVIG improves quality of life by reducing infection frequency.

Main Methods:

• Retrospective cohort study of 52 CLL patients receiving IVIG for hypogammaglobulinemia and recurrent infections (2005-2022).
• Analysis of infectious events in the 12 months before and after IVIG initiation.
• Statistical analysis to determine the risk reduction of grade ≥ 2 infections.

Main Results:

• IVIG initiation reduced grade ≥ 2 infections by 67% (RR 0.33, p < 0.0001).
• The incidence of grade ≥ 2 infections decreased from 100% to 33% post-IVIG.
• Mean infections per patient dropped from 2.1 to 0.4, with a number needed to treat of 1.5.

Conclusions:

• IVIG therapy is associated with a significant reduction in severe infections for CLL patients with hypogammaglobulinemia.
• IVIG may improve patient quality of life by mitigating infection burden.
• Baseline immunoglobulin levels and recent CLL treatment did not predict post-IVIG infection risk.